Piramal Pharma Limited - search results

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fentanyl-piramal 0,05 mg/ml inj. sol. i.m./i.v./s.c. amp.

piramal critical care b.v. - fentanyl citrate 0,0785 mg/ml - eq. fentanyl 0,05 mg/ml - solution for injection - 0,05 mg/ml - fentanyl citrate 0.0785 mg/ml - fentanyl

Israel - English - Ministry of Health

sojourn sevoflurane usp

pharma medis - sevoflurane - liquid - sevoflurane 100 %v/v - sevoflurane - sevoflurane - general inhalation anesthetic.

United States - English - NLM (National Library of Medicine)

tetrabenazine tablet

slate run pharmaceuticals, llc - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine tablets are indicated for the treatment of chorea associated with huntington’s disease. tetrabenazine tablets are contraindicated in patients: risk summary there are no adequate data on the developmental risk associated with the use of tetrabenazine tablets in pregnant women. administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspring mortality. administration of a major human metabolite of tetrabenazine to rats during pregnancy or during pregnancy and lactation produced adverse effects on the developing fetus and offspring (increased mortality, decreased growth, and neurobehavioral and reproductive impairment). the adverse developmental effects of tetrabenazine and a major human metabolite of tetrabenazine in rats occurred at clinically relevant doses [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 t

United States - English - NLM (National Library of Medicine)

allopurinol tablet

northstar rxllc - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol tablets reduces serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings, and precautions). allopurinol tablets are indicated in: - the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). - the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. - the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day